As filed with the Securities and Exchange
Commission on June 2, 2020
Registration No. 333-
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM F-3
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
China Ceramics Co., Ltd.
(Exact name of registrant as specified
in its charter)
British Virgin Islands
|
|
Not Applicable
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
c/o Jinjiang Hengda Ceramics Co., Ltd.
Junbing Industrial Zone, Anhai, Jinjiang
City, Fujian Province, PRC
Tel: +86 (595) 8576 5053
Fax: +86 (595) 8576 5059
(Address and telephone number of registrant’s
principal executive offices)
Copies to:
Ralph V. De Martino, Esq.
F. Alec Orudjev, Esq.
Schiff Hardin LLP
901 K Street NW, Suite 700, Washington,
DC 20001
Tel: (202)724-6848
Fax: (202) 778-6460
Approximate date of commencement of proposed sale to the public:
From time to time after the effective date of this Registration Statement.
If the only securities being registered on this Form are being
offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨
If any of the securities being registered on this Form are to
be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. x
If this Form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. ¨
If this Form is a registration statement
pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the SEC
pursuant to Rule 462(e) under the Securities Act, check the following box. ¨
If this Form is a post-effective amendment
to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes
of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
Emerging growth company ¨
If an emerging growth company that prepares
its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B)
of the Securities Act.¨
CALCULATION OF REGISTRATION FEE
Title of Security Being Registered
|
|
Amount Being
Registered (1)
|
|
|
Proposed
Maximum
Aggregate
Offering
Price per
Share (2)
|
|
|
Proposed
Maximum
Aggregate
Offering
Price
|
|
|
Amount of
Registration
Fee
|
|
Shares, par value $0.008 per share, underlying common share warrants to be offered by the selling shareholders
|
|
|
2,473,245
|
|
|
$
|
0.65
|
|
|
$
|
1,607,609.2
|
|
|
$
|
208.67
|
|
(1) Includes 1,200,000 of our common shares
issuable upon the exercise of warrants at an exercise price of $0.82 per share, 60,000 of our common shares issuable upon the exercise
of placement agent warrants at an exercise price of $0.9375 per share, 1,102,950 of our common shares issuable upon the exercise
of warrants at an exercise price of $0.79 per share, and 110,295 of our common shares issuable upon the exercise of placement agent
warrants at an exercise price of $0.85 per share. All of the shares being registered are offered by the Selling Shareholders listed
in the registration statement. Accordingly, this registration statement includes an indeterminate number of additional shares of
common stock issuable for no additional consideration pursuant to any stock dividend, stock split, recapitalization or other similar
transaction effected without the receipt of consideration, which results in an increase in the number of outstanding shares of
our common stock. In the event of a stock split, stock dividend or similar transaction involving our common stock, in order to
prevent dilution, the number of shares registered shall be automatically increased to cover the additional shares in accordance
with Rule 416(a) under the Securities Act of 1933.
(2) Estimated solely for
the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended, based on
the average of the high and low prices per share of the registrant’s shares as reported on the Nasdaq Capital Market on May
28, 2020.
The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment
which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until this Registration Statement shall become effective on such date as the Securities and Exchange
Commission, acting pursuant to said Section 8(a), may determine.
The information in this
prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell securities and it is not soliciting an
offer to buy securities in any state where the offer or sale is not permitted.
Subject to Completion,
Dated June 2, 2020
PROSPECTUS
2,473,245 common shares
issuable upon exercise of outstanding
warrants
offered by the Selling Shareholders
of
China Ceramics Co., Ltd.
This prospectus relates
to the resale of:
|
·
|
up to 1,200,000 of our common shares issuable upon the exercise of warrants at an exercise price
of $0.82 per share (the “December 2019 Warrants”),
|
|
·
|
up to 60,000 of our common shares issuable upon the exercise
of placement agent warrants at an exercise price of $0.9375 per share (the “December 2019 Placement Agent Warrants”),
|
|
·
|
up to 1,102,950 of our common shares issuable upon the exercise of warrants at an exercise price
of $0.79 per share (the “May 2020 Warrants”), and
|
|
·
|
up to 110,295 of our common shares issuable upon the exercise of placement agent warrants at an
exercise price of $0.85 per share (the “May 2020 Placement Agent Warrants”).
|
The common shares issuable
upon conversion of such warrants may be offered for sale from time to time by the Selling Shareholders named in this prospectus.
We will receive proceeds from any exercises of the warrants, but not from the sale of the underlying common stock.
The Selling Shareholders
may sell any or all of the Shares on any stock exchange, market or trading facility on which the Shares are traded or in privately
negotiated transactions at fixed prices that may be changed, at market prices prevailing at the time of sale or at negotiated prices.
Information on the Selling Shareholders and the times and manners in which they may offer and sell our Shares is described under
the sections entitled “Selling Shareholders” and “Plan of Distribution” in this prospectus. While we will
bear all costs, expenses and fees in connection with the registration of the Shares, we will not receive any of the proceeds from
the sale of our Shares by the Selling Shareholders.
Our Shares are currently
traded on the Nasdaq Stock Market under the symbol “CCCL”. On May 28, 2020, the closing price for our Shares on Nasdaq
was $0.63 per share.
We may amend or supplement
this prospectus from time to time by filing amendments or supplements as required.
Investing in our securities involves
risks. See “Risk Factors” beginning on page 6 of this prospectus.
Neither
the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved
of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal
offense.
Prospectus dated June 2, 2020
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we
filed with the Securities and Exchange Commission. Under this registration process, the selling shareholders may from time to time
sell up to 2,473,245 common shares in one or more offerings. This prospectus provides you with a general description of the securities
that our selling shareholders may offer. Specific information about the offering may also be included in a prospectus supplement,
which may update or change information included in this prospectus. You should read both this prospectus and any prospectus supplement
together with additional information described under the heading “Where You Can Find More Information.”
You should rely only
on the information contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectus
prepared by or on our behalf. Neither we, nor the selling shareholders, have authorized any other person to provide you with different
or additional information. Neither we, nor the selling shareholders, take responsibility for, nor can we provide assurance as to
the reliability of, any other information that others may provide. The selling shareholders are not making an offer to sell these
securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is accurate
only as of the date of this prospectus or such other date stated in this prospectus, and our business, financial condition, results
of operations and/or prospects may have changed since those dates.
Except as otherwise
set forth in this prospectus, neither we nor the selling shareholders have taken any action to permit a public offering of these
securities outside the United States or to permit the possession or distribution of this prospectus outside the United States.
Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions
relating to the offering of these securities and the distribution of this prospectus outside the United States.
Certain Defined Terms and Conventions
Unless otherwise indicated,
references in this prospectus to:
|
•
|
“China” or the “PRC” are to the People’s Republic of China, excluding, for the purpose of this prospectus only, Taiwan and the special administrative regions of Hong Kong and Macau.
|
|
•
|
“RMB” and “Renminbi” are to the legal currency of China (see “Exchange Rate Information” for translations of RMB into U.S. dollars in this prospectus). This prospectus contains translations of certain RMB amounts into U.S. dollar amounts at specified rates. Unless otherwise stated, the translations of RMB into U.S. dollars have been made at the exchange rate as set forth on May 1, 2020 in the H.10 statistical release of the Federal Reserve Board, which was RMB 7.0622 to US $1.00. We make no representation that the RMB or U.S. dollar amounts referred to in this prospectus could have been or could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all (also see “Risk Factors”).
|
|
•
|
“shares” are to our shares, par value US$0.008 per share.
|
|
•
|
“US$” and “U.S. dollars” are to the legal currency of the United States.
|
|
•
|
“we,” “us,” “our,” and “China Ceramics” refers to China Ceramics Co., Ltd., a British Virgin Islands company, and its subsidiaries, including Success Winner Limited (“Success Winner”), a British Virgin Islands company and wholly owned subsidiary of China Ceramics, Stand Best Creation Limited (“Stand Best”), a Hong Kong company and wholly owned subsidiary of Success Winner and the entity that wholly owns Jinjiang Hengda Ceramics Co., Ltd. (“Hengda”), a PRC operating company that in turn wholly owns Jiangxi Hengdali Ceramic Materials Co., Ltd. (“Hengdali”), and Fujian Province Hengdali Building Materials Co., Ltd. each a PRC operating company.
|
WHERE YOU CAN FIND MORE INFORMATION
We have filed with
the SEC a registration statement on Form F-3 under the Securities Act of 1933, as amended (the “Securities Act”) with
respect to the Shares offered under this prospectus. For the purposes of this section, the term registration statement means the
original registration statement and any and all amendments including the schedules and exhibits to the original registration statement
or any amendment. This prospectus does not contain all of the information included in the registration statement we filed. For
further information regarding us and the Shares offered in this prospectus, you may desire to review the full registration statement,
including the exhibits. The registration statement, including its exhibits and schedules, may be inspected and copied at the public
reference facilities maintained by the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information
on the operation of the public reference room by calling 1-202-551-8090. Copies of such materials are also available by mail from
the Public Reference Branch of the SEC at 100 F Street, N.E., Washington, D.C. 20549 at prescribed rates. In addition, the SEC
maintains a website (http://www.sec.gov) from which interested persons can electronically access the registration statement,
including the exhibits and schedules to the registration statement.
We are subject to the
reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are applicable
to a foreign private issuer. In accordance with the Exchange Act, we file reports with the SEC, including annual reports on Form
20-F. We also furnish to the SEC under cover of Form 6-K material information required to be made public in the British Virgin
Islands, filed with and made public by any stock exchange or automated quotation system or distributed by us to our shareholders.
As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy
statements to shareholders. In addition, our officers, directors and principal shareholders are exempt from the “short-swing
profits” reporting and liability provisions contained in Section 16 of the Exchange Act and related Exchange Act rules.
INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE
The SEC allows us to
“incorporate by reference” the information we file with them. This means that we can disclose important information
to you by referring you to those documents. Each document incorporated by reference is current only as of the date of such document,
and the incorporation by reference of such documents should not create any implication that there has been no change in our affairs
since the date thereof or that the information contained therein is current as of any time subsequent to its date. The information
incorporated by reference is considered to be a part of this prospectus and should be read with the same care. When we update the
information contained in documents that have been incorporated by reference by making future filings with the SEC, the information
incorporated by reference in this prospectus is considered to be automatically updated and superseded. In other words, in the case
of a conflict or inconsistency between information contained in this prospectus and information incorporated by reference into
this prospectus, you should rely on the information contained in the document that was filed later.
We incorporate by reference
the documents listed below:
|
•
|
our Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the SEC on May 20, 2020;
|
|
•
|
with respect to each offering of securities under this prospectus, all our subsequent Annual Reports on Form 20-F and any report on Form 6-K that (i) we file or furnish with the SEC on or after the date on which this prospectus is first filed with the SEC and until the termination or completion of the offering under this prospectus and (ii) indicates that it is being incorporated by reference in this prospectus.
|
Unless expressly incorporated
by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to, but not filed with,
the SEC. We will provide to each person, including any beneficial owner, who receives a copy of this prospectus, upon written or
oral request, without charge, a copy of any or all of the documents we refer to above which we have incorporated by reference in
this prospectus, except for exhibits to such documents unless the exhibits are specifically incorporated by reference into this
prospectus. You should direct your requests to the attention of our chief financial officer at our principal executive office located
in c/o Junbing Industrial Zone, Anhai, Jinjiang City, Fujian Province, PRC. Our telephone number at this address is +86 (595) 8576
5053 and our fax number is Fax: +86 (595) 8576 5059.
You should rely only
on the information contained or incorporated by reference in this prospectus, in any applicable prospectus supplement or any related
free writing prospectus that we may authorize to be delivered to you. We have not authorized any other person to provide you with
different information. If anyone provides you with different or inconsistent information, you should not rely on it. We will not
make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the
information appearing in this prospectus, the applicable supplement to this prospectus or in any related free writing prospectus
is accurate as of its respective date, and that any information incorporated by reference is accurate only as of the date of the
document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and
prospects may have changed since those dates.
PROSPECTUS SUMMARY
Our Business
We are a leading
Chinese manufacturer of ceramic tiles used for exterior siding and for interior flooring and design in residential and commercial
buildings. The ceramic tiles, sold under the “HD” or “Hengda,” “HDL” or “Hengdeli”,
“Pottery Capital of Tang Dynasty”, “TOERTO” and ”WULIQIAO” brands are available in over two
thousand styles, colors and size combinations. Currently, we have five principal product categories: porcelain tiles, glazed tiles,
glazed porcelain tiles, rustic tiles, and polished glazed tiles. Ceramic tiles are widely used in the PRC as a construction material
for residential and commercial buildings. Ceramic tiles are used for flooring, interior walls for decorative purposes and on exterior
siding due to their resistance to temperature, extreme environments, erosion, abrasion and discoloration for extended periods of
time. Our manufacturing facilities operated by Jinjiang Hengda Ceramics Co., Ltd. are located in Jinjiang, Fujian Province, and
our manufacturing facilities operated by Jiangxi Hengdali Ceramic Materials Co., Ltd. are located in Gaoan, Jiangxi Province.
Corporate Information
Our principal executive
office is located at Junbing Industrial Zone, Anhai, Jinjiang City, Fujian Province, People’s Republic of China. Our telephone
number at this address is +86 595 8576 5053. Our registered office is Craigmuir Chambers, Road Town, Tortola, British Virgin Islands,
and our registered agent is Harneys Corporate Services Limited. We maintain a website at http://www.cceramics.com that contains
information about our company. Information on this web site is not part of this prospectus.
December 2019 Private Placement
On December 16, 2019,
the Company entered into a Securities Purchase Agreement with certain institutional investors for the sale by the Company of 1,200,000
common shares at a purchase price of $0.75 per share. Concurrently with the sale of its common shares, pursuant to a Purchase Agreement
the Company also sold common share purchase warrants to purchase 1,200,000 common shares of the Company (the “Warrant Shares”).
Subject to certain beneficial ownership limitations, the five-year warrants will be initially exercisable on the six-month anniversary
of the issuance date at an exercise price equal to $0.82 per share, subject to adjustments, and will terminate on the five-year
anniversary of the initial exercise date of the warrants. The closing of this offering took place on December 18, 2019. The Company
received net proceeds from the transactions of approximately $748,000, after deducting certain fees due to the placement agent
and the Company’s estimated transaction expenses. The net proceeds received by the Company from the transactions were used
for working capital and general corporate purposes. The warrants and the Warrant Shares were sold without registration under the
Securities Act of 1933 (the “Securities Act”) in reliance on the exemptions provided by Section 4(a)(2) of the Securities
Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors,
and in reliance on similar exemptions under applicable state laws.
Dawson James Securities,
Inc. acted as the Company’s exclusive placement agent (the “Placement Agent”), on a best efforts basis, in connection
with the offering. Pursuant to the terms and provisions of the engagement letter between the Company and the Placement Agent, the
Company agreed to pay the Placement Agent a cash placement fee equal to 8% of the gross proceeds of the Offering, or $72,000, plus
other expenses of the Placement Agent not to exceed $45,000. The Placement Agent also received five-year warrants to purchase up
to 60,000 common shares (or 5% of the aggregate number of shares sold in the offering), which such compensation warrants have substantially
the same terms as the Warrants sold in the Offering, except that such Placement Agent warrants have an exercise price of $0.9375
per share and will terminate on the five-year anniversary of the effective date of this offering.
May 2020 Private
Placement
On May 22,
2020, the Company entered into a Securities Purchase Agreement with certain institutional investors for the sale by the Company
of 1,102,950 common shares at a purchase price of $0.68 per share. Concurrently with the sale of the common shares, pursuant to
the Purchase Agreement the Company also sold warrants to purchase 1,102,950 common shares. The Company sold the common shares and
Warrants for aggregate gross proceeds of $750,006. Subject to certain beneficial ownership limitations, the five-year warrants
will be initially exercisable on the six-month anniversary of the issuance date at an exercise price equal to $0.79 per share,
subject to adjustments as provided under the terms of the Warrants, and will terminate on the five-year anniversary of the initial
exercise date of the Warrants. The net proceeds from the transactions will be approximately $595,000, after deducting certain fees
due to the placement agent and the Company’s estimated transaction expenses, and were used for working capital and general
corporate purposes. The warrants and the shares issuable upon exercise of the Warrants were sold without registration under the
Securities Act of 1933 in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving
a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar
exemptions under applicable state laws.
Dawson James
Securities, Inc. acted as the Company’s exclusive placement agent, on a best-efforts basis, in connection with the Offering.
Pursuant to the terms and provisions of the engagement letter between the Company and the Placement Agent, the Company agreed to
pay the Placement Agent a cash placement fee equal to 8% of the gross proceeds of the Offering, or $60,000, plus other expenses
of the Placement Agent not to exceed $45,000. The Placement Agent also received five-year warrants to purchase up to 101,295 common
shares (or 5% of the aggregate number of shares sold in the offering), which such compensation warrants have substantially the
same terms as the Warrants sold in the Offering, except that such Compensation Warrants have an exercise price of $0.85 per share
and will terminate on the five year anniversary of the effective date of this offering.
RISK FACTORS
Any investment in
the common shares of Company is speculative and involves a high degree of risk. Before making an investment decision, you should
carefully consider the risks described under “Risk Factors” in our most recent Annual Report on Form 20-F, or any updates
in our reports on Form 6-K, together with all of the other information appearing in, or incorporated by reference into, this prospectus
and any applicable prospectus supplement. The risks so described are not the only risks facing our company. Additional risks not
presently known to us or that we currently deem immaterial may also impair our business operations. Our business, financial condition
and results of operations could be materially adversely affected by any of these risks. The trading price of our securities could
decline due to any of these risks, and you may lose all or part of your investment.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some of the information
in this prospectus, any prospectus supplement, and the documents we incorporate by reference contains forward-looking statements
within the meaning of the federal securities laws. You should not rely on forward-looking statements in this prospectus, any prospectus
supplement, or the documents we incorporate by reference. Forward-looking statements typically are identified by use of terms such
as “anticipate,” “believe,” “plan,” “expect,” “future,” “intend,”
“may,” “will,” “should,” “estimate,” “predict,” “potential,”
“continue,” and similar words, although some forward-looking statements are expressed differently. This prospectus,
any prospectus supplement, and the documents we incorporate by reference may also contain forward-looking statements attributed
to third parties relating to their estimates regarding the growth of our markets. All forward-looking statements address matters
that involve risks and uncertainties, and there are many important risks, uncertainties and other factors that could cause our
actual results, as well as those of the markets we serve, levels of activity, performance, achievements and prospects to differ
materially from the forward-looking statements contained in this prospectus, any prospectus supplement, and the documents we incorporate
by reference.
You should also consider
carefully the statements under “Risk Factors” and other sections of this prospectus, any prospectus supplement, and
the documents we incorporate by reference, which address additional facts that could cause our actual results to differ from those
set forth in the forward-looking statements. We caution investors not to place significant reliance on the forward-looking statements
contained in this prospectus, any prospectus supplement, and the documents we incorporate by reference. We undertake no obligation
to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.
PRICE RANGE OF OUR SHARES
Our shares have been
listed on the NASDAQ Stock Market under the symbols CCCL, since January 18, 2011. Our shares were listed on the NASDAQ Capital
Market from November 3, 2010 through January 17, 2011 and were relisted on the Nasdaq Capital Market on March 23, 2016 following
the listing transfer where it is trading now under the same symbol “CCCL.” Our shares were listed on the NASDAQ Global
Market from January 18, 2011 until March 22, 2016. The shares were previously quoted on the OTC Bulletin Board from December 29,
2009 through November 2, 2010.
The following tables
set forth, for the calendar quarters indicated and through April 2020, the quarterly high and low sale prices for our shares,
as reported on NASDAQ Stock Market, the OTC Bulletin Board or the NYSE Amex, as applicable. The OTC Bulletin Board market quotations
reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily reflect actual transactions.
|
|
Shares
|
|
|
|
High
|
|
|
Low
|
|
Annual Highs and Lows
|
|
|
|
|
|
|
|
|
2012
|
|
|
36.32
|
|
|
|
11.76
|
|
2013
|
|
|
32.48
|
|
|
|
15.84
|
|
2014
|
|
|
20.48
|
|
|
|
5.92
|
|
2015
|
|
|
11.36
|
|
|
|
6.00
|
|
2016
|
|
|
8.64
|
|
|
|
2.09
|
|
|
|
|
|
|
|
|
|
|
Quarterly Highs and Lows
|
|
|
|
|
|
|
|
|
2017
|
|
|
|
|
|
|
|
|
First Quarter
|
|
|
2.53
|
|
|
|
2.08
|
|
Second Quarter
|
|
|
2.26
|
|
|
|
1.32
|
|
Third Quarter
|
|
|
1.68
|
|
|
|
1.31
|
|
Fourth Quarter
|
|
|
2.39
|
|
|
|
1.32
|
|
|
|
|
|
|
|
|
|
|
2018
|
|
|
|
|
|
|
|
|
First Quarter
|
|
|
2.69
|
|
|
|
1.43
|
|
Second Quarter
|
|
|
1.76
|
|
|
|
1.37
|
|
Third Quarter
|
|
|
1.87
|
|
|
|
1.32
|
|
Fourth Quarter
|
|
|
3.67
|
|
|
|
0.80
|
|
|
|
|
|
|
|
|
|
|
2019
|
|
|
|
|
|
|
|
|
First Quarter
|
|
|
2.08
|
|
|
|
1.38
|
|
Second Quarter
|
|
|
1.76
|
|
|
|
0.80
|
|
Third Quarter
|
|
|
0.93
|
|
|
|
0.73
|
|
Fourth
|
|
|
1.06
|
|
|
|
0.67
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
|
|
|
|
|
|
|
January
|
|
|
0.90
|
|
|
|
0.67
|
|
February
|
|
|
0.73
|
|
|
|
0.51
|
|
March
|
|
|
0.55
|
|
|
|
0.27
|
|
April
|
|
|
0.75
|
|
|
|
0.38
|
|
On May 28, 2020, the
closing price of our Shares on the NASDAQ Stock Market was $0.63. As of May 22, 2020, there were 8,015,084 of our common shares
issued and outstanding.
CAPITALIZATION
The following table
sets forth our capitalization as of December 31, 2019. Because we will not be receiving any proceeds pursuant to the sale of any
Shares by the selling shareholders, our capitalization table is not adjusted to reflect such sales. You should read the following
table in conjunction with our financial statements, which are incorporated by reference into this prospectus.
Capitalization
|
|
As of
|
|
(in RMB except share data)
|
|
December 31, 2019
|
|
Common shares
|
|
|
7,306,985
|
|
Par Value Amount
|
|
|
397,016
|
|
Additional Paid-In Capital
|
|
|
440,004,143
|
|
Statutory Reserves
|
|
|
135,343,158
|
|
Retained Earnings
|
|
|
(300,972,020
|
)
|
Accumulated Other Comprehensive Income
|
|
|
(1,879,723
|
)
|
Total:
|
|
|
272,892,574
|
|
USE OF PROCEEDS
We will not receive
any proceeds from the sale of any shares by the selling shareholders. The selling shareholders will receive all of the net proceeds
from the sale of any shares offered by them under this prospectus. The selling shareholders will pay any underwriting discounts
and commissions and expenses incurred by the selling shareholders for brokerage, accounting, tax, legal services or any other expenses
incurred by the selling shareholders in disposing of these shares. We will bear all other costs, fees and expenses incurred in
effecting the registration of the shares covered by this prospectus.
DIVIDEND POLICY
We paid a cash dividend
of US$0.10 (equivalent to RMB0.61) per share each on July 13, 2013 and January 14, 2014, respectively, to our shareholders which
totaled in aggregate US$4.1 million (equivalent to RMB24.9 million). Also, we paid a cash dividend of US$0.0125 (equivalent to
RMB0.08) per share each on July 14, 2014 and January 14, 2015, respectively, to its shareholders which totaled in aggregate US$0.5
million (equivalent to RMB3.2 million).
We do not currently
have any plans to pay any cash dividends in the foreseeable future on our shares being sold in this offering. We currently intend
to retain most, if not all, of our available funds and any future earnings to operate and expand our business. The payment of dividends
by entities organized in China is subject to limitations. Regulations in the PRC currently permit payment of dividends only out
of accumulated profits as determined in accordance with PRC accounting standards and regulations. Each of our Chinese subsidiaries
is also required to set aside at least 10% of its after-tax profit based on China’s accounting standards each year to its
general reserves until the cumulative amount of such reserves reach 50% of its registered capital. These reserves are not distributable
as cash dividends. The board of directors of our PRC subsidiaries, each of which is a wholly foreign owned enterprise, has the
discretion to allocate a portion of its after-tax profits to its staff welfare and bonus funds, which is likewise not distributable
to its equity owners except in the event of a liquidation of the foreign-invested enterprise. If we decide to pay dividends in
the future, these restrictions may impede our ability to pay dividends. In addition, if any of these Chinese entities incurs debt
on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions
to us.
Our Board of Directors
has discretion on whether to pay dividends. Even if our board of directors decides to pay dividends, the form, frequency and amount
will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual
restrictions and other factors that our board of directors may deem relevant.
SELLING SHAREHOLDERS
This prospectus covers
the public resale of the shares owned by the selling shareholders named below. Such selling shareholders may from time to time
offer and sell pursuant to this prospectus any or all of the shares owned by them. The selling shareholders, however, make no representations
that the shares will be offered for sale. The tables below present information regarding the selling shareholders and the shares
that each such selling shareholder may offer and sell from time to time under this prospectus.
The shares being registered
by the selling shareholders represent our securities sold and issued in the December 2019 private placement of our securities.
Unless otherwise indicated, all information with respect to ownership of our Shares of the selling shareholders has been furnished
by or on behalf of the selling shareholders and is as of May 22, 2020. We believe, based on information supplied by the selling
shareholders, that except as may otherwise be indicated in the footnotes to the tables below, the selling shareholders have sole
voting and dispositive power with respect to the Shares reported as beneficially owned by them. Because the selling shareholders
identified in the tables may sell some or all of the Shares owned by them which are included in this prospectus, and because, except
as set forth herein, there are currently no agreements, arrangements or understandings with respect to the sale of any of the Shares,
no estimate can be given as to the number of Shares available for resale hereby that will be held by the selling shareholders upon
termination of this offering. In addition, the selling shareholders may have sold, transferred or otherwise disposed of, or may
sell, transfer or otherwise dispose of, at any time and from time to time, the Shares they hold in transactions exempt from the
registration requirements of the Securities Act after the date on which they provided the information set forth on the table below.
We have, therefore, assumed for the purposes of the following table, that the selling shareholders will sell all of the Shares
owned beneficially by them that are covered by this prospectus, but will not sell any other Ordinary Shares that they presently
own. However, we are not aware of any agreements, arrangements or understandings with respect to the sale of any of the Shares
by any of the selling shareholders. Beneficial ownership for the purposes of this table is determined in accordance with the rules
and regulations of the SEC. These rules generally provide that a person is the beneficial owner of securities if such person has
or shares the power to vote or direct the voting thereof, or to dispose or direct the disposition thereof or has the right to acquire
such powers within 60 days.
The selling shareholders
and intermediaries through whom such securities are sold may be deemed “underwriters” within the meaning of the Securities
Act with respect to the Shares offered by this prospectus, and any profits realized or commissions received may be deemed underwriting
compensation. Additional selling shareholders not named in this prospectus will not be able to use this prospectus for resales
until they are named in the tables above by prospectus supplement or post-effective amendment. Transferees, successors and donees
of identified selling shareholders will not be able to use this prospectus for resales until they are named in the tables above
by prospectus supplement or post-effective amendment. If required, we will add transferees, successors and donees by prospectus
supplement in instances where the transferee, successor or donee has acquired its Shares from holders named in this prospectus
after the effective date of this prospectus.
The following table sets forth:
|
•
|
the name of each selling shareholder holding Shares;
|
|
•
|
the number of Shares beneficially owned by each selling shareholder prior to the sale of the Shares covered by this prospectus;
|
|
•
|
the number of Shares that may be offered by each selling shareholder pursuant to this prospectus;
|
|
•
|
the number of Shares to be beneficially owned by each selling shareholder following the sale of the Shares covered by this prospectus; and
|
|
•
|
the percentage of our issued and outstanding Shares to be owned by each selling shareholder before and after the sale of the Shares covered by this prospectus.
|
Name of Selling Shareholder
|
|
Number of
Shares
Beneficially
Owned
Prior to this
Offering
|
|
|
Percent of
Outstanding
Shares
Beneficially
Owned
Before Sale
of Shares (4)
|
|
|
Number of
Shares
Available
Pursuant to
this
Prospectus
|
|
|
Number of
Shares
Beneficially
Owned
After Sale
of Shares (5)
|
|
|
Percent of
Outstanding
Shares
Beneficially
Owned
After Sale
of Shares (5)
|
|
Anson Investments Master Fund LP (1)
|
|
|
767,650
|
|
|
|
4.99
|
%
|
|
|
767,650
|
|
|
|
0
|
|
|
|
0
|
%
|
CVI Investments, Inc. (2)
|
|
|
767,650
|
|
|
|
4.99
|
%
|
|
|
767,650
|
|
|
|
0
|
|
|
|
0
|
%
|
Intracoastal Capital, LLC (3)
|
|
|
845,150
|
|
|
|
4.99
|
%
|
|
|
845,150
|
|
|
|
77,500
|
|
|
|
|
*
|
Dawson James Securities, Inc. (6)
|
|
|
102,177
|
|
|
|
|
*
|
|
|
102,177
|
|
|
|
0
|
|
|
|
0
|
|
Robert Keyser, Jr. (7)
|
|
|
34,059
|
|
|
|
|
*
|
|
|
34,059
|
|
|
|
0
|
|
|
|
0
|
|
Douglas Armstrong (8)
|
|
|
34,059
|
|
|
|
|
*
|
|
|
34,059
|
|
|
|
0
|
|
|
|
0
|
|
*
|
Less than 1%.
|
(1)
|
The address of the selling shareholder is 155 University Avenue, Suite 207, Toronto, Ontario, Canada M5H 3B7.
|
(2)
|
The address of the selling shareholder is c/o Heights Capital Management, 101 California
Street, Suite 3250, San Francisco, CA 94111. Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc. ("CVI"), has
discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares.
Martin Kobinger, in his capacity as Investment Manager of Heights Capital Management, Inc., may also be deemed to have investment
discretion and voting power over the shares held by CVI. Mr. Kobinger disclaims any such beneficial ownership of the shares. CVI
Investments, Inc.is affiliated with one or more FINRA member, none of whom are currently expected to participate in the sale pursuant
to the prospectus contained in the Registration Statement of shares purchased by the investor in the offering.
|
(3)
|
The address of the selling shareholder is 2211A Lakeside Drive, Bannockburn, IL 60015.
|
(4)
|
Based on 8,015,084 shares outstanding as of the date of this prospectus; subject to the
4.99% beneficial ownership blocker provisions.
|
(5)
|
Assumes that the selling shareholder sells all of the shares offered hereby.
|
(6)
|
Includes (i) 36,000 common shares issuable exercise of the 2019
Placement Agent Warrants, and (ii) 66,177 common shares issuable exercise of the 2020 Placement Agent Warrants.
Dawson James Securities, Inc. is a securities broker-dealer and FINRA member. The address of the selling shareholder is 1 North
Federal Highway, 5th Floor, Boca Raton, FL 33432.
|
(7)
|
Includes (i) 12,000 common shares issuable exercise of the 2019
Placement Agent Warrants, and (ii) 22,059 common shares issuable exercise of the 2020 Placement Agent Warrants.
Mr. Keyser disclaims beneficial ownership of the securities owned by Dawson James Securities Inc.
|
(8)
|
Includes (i) 12,000 common shares issuable exercise of the 2019
Placement Agent Warrants, and (ii) 22,059 common shares issuable exercise of the 2020 Placement Agent Warrants.
Mr. Armstrong disclaims beneficial ownership of the securities owned by Dawson James Securities Inc.
|
PLAN OF DISTRIBUTION
The selling shareholders,
which as used herein includes donees, pledgees, transferees or other successors-in-interest selling Shares or interests in Shares
received after the date of this prospectus from a selling shareholder as a gift, pledge, partnership distribution or other transfer,
may, from time to time, sell, transfer or otherwise dispose of any or all of the Shares on any stock exchange, market or trading
facility on which the Shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market
prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale,
or at negotiated prices.
The selling shareholders may use any one or more of the following
methods when disposing of Shares:
|
•
|
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
|
|
•
|
block trades in which the broker-dealer will attempt to sell the Shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
|
|
•
|
purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
|
|
•
|
an exchange distribution in accordance with the rules of the applicable exchange;
|
|
•
|
privately negotiated transactions;
|
|
•
|
short sales effected after the date the registration statement of which this prospectus is a part is declared effective by the SEC;
|
|
•
|
through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
|
|
•
|
broker-dealers may agree with the selling shareholders to sell a specified number of such Shares at a stipulated price per share;
|
|
•
|
a combination of any such methods of sale; and
|
|
•
|
any other method permitted by applicable law.
|
The selling shareholders
may, from time to time, pledge or grant a security interest in some or all of the Shares owned by them and, if they default in
the performance of their secured obligations, the pledgees or secured parties may offer and sell the Shares, from time to time,
under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities
Act amending the list of selling shareholders to include the pledgee, transferee or other successors in interest as selling shareholders
under this prospectus. The selling shareholders also may transfer the Shares in other circumstances, in which case the transferees,
pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.
In connection with
the sale of their Shares or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of such Shares in the course of hedging the positions
they assume. The selling shareholders may also sell Shares short and deliver these securities to close out their short positions,
or loan or pledge the Shares to broker-dealers that in turn may sell these securities. The selling shareholders may also enter
into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative
securities which require the delivery to such broker-dealer or other financial institution of the Shares offered by this prospectus,
which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended
to reflect such transaction).
The aggregate proceeds
to the selling shareholders from the sale of the Shares offered by them will be the purchase price of such Shares less discounts
or commissions, if any. Each of the selling shareholders reserves the right to accept and, together with their agents from time
to time, to reject, in whole or in part, any proposed purchase of ordinary shares to be made directly or through agents. We will
not receive any of the proceeds from the resale of the Shares.
The selling shareholders
also may resell all or a portion of their Ordinary Shares in open market transactions in reliance upon Rule 144 under the Securities
Act, provided that they meet the criteria and conform to the requirements of that rule.
The selling shareholders
and any underwriters, broker-dealers or agents that participate in the sale of the Shares therein may be “underwriters”
within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on
any resale of the Ordinary Shares may be underwriting discounts and commissions under the Securities Act. Selling shareholders
who are “underwriters” within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus
delivery requirements of the Securities Act.
To the extent required,
the Shares to be sold, the names of the selling shareholders, the respective purchase prices and public offering prices, the names
of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth
in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes
this prospectus.
In order to comply
with the securities laws of some states, if applicable, the Shares may be sold in these jurisdictions only through registered or
licensed brokers or dealers. In addition, in some states the Shares may not be sold unless it has been registered or qualified
for sale or an exemption from registration or qualification requirements is available and is complied with.
We have advised the
selling shareholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of Shares in the
market and to the activities of the selling shareholders and their affiliates. In addition, to the extent applicable, we will make
copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling shareholders for the
purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling shareholders may indemnify any broker-dealer
that participates in transactions involving the sale of the Shares against certain liabilities, including liabilities arising under
the Securities Act. We have agreed to indemnify the selling shareholders against liabilities, including liabilities under the Securities
Act and state securities laws, relating to the registration of the Ordinary Shares offered by this prospectus.
EXPENSES
We estimate the fees
and expenses to be incurred by us in connection with the resale of the ordinary shares in this offering, other than underwriting
discounts and commissions, to be as follows:
SEC registration fee
|
|
$
|
208.59
|
|
Legal fees and expenses
|
|
$
|
10,000
|
|
Accounting fees and expenses
|
|
$
|
10,000
|
|
Miscellaneous expenses
|
|
$
|
2,500
|
|
|
|
|
|
|
Total
|
|
$
|
22,708.59
|
|
All amounts are estimated except the SEC
registration fee.
LEGAL MATTERS
We are being represented
by Schiff Hardin LLP, Washington, DC with respect to legal matters of United States federal securities. The validity of the shares
offered in this offering and legal matters as to British Virgin Islands law will be passed upon for us by Harney Westwood &
Riegels. Legal matters will be passed upon for any underwriters, dealers or agents by counsel named in the applicable prospectus
supplement.
EXPERTS
The financial
statements incorporated by reference in this prospectus have been audited by Centurion ZD CPA & Co., our independent
registered public accounting firm, and are included in reliance upon such reports given upon the authority of said firm as
experts in auditing and accounting.
ENFORCEABILITY OF CIVIL LIABILITIES
Many of our officers
and directors, and some of the experts named in this prospectus, are residents of PRC or elsewhere outside of the U.S., and all
of our assets and the assets of such persons are located outside the U.S. As a result, it may be difficult for investors in the
U.S. to effect service of process within the U.S. upon such directors, officers and representatives of experts who are not residents
of the U.S. or to enforce against them judgments of a U.S. court predicated solely upon civil liability under U.S. federal securities
laws or the securities laws of any state within the U.S.
Substantially all of
our operations and records, and most of our senior management are located in the PRC. Our shareholders have limited ability to
assert and collect on claims in litigation against us and our principals. In addition, corporate organization and structure could
further impede the ability of a person to prove a claim or collect on a judgment against the Company. Finally, China has very restrictive
secrecy laws that prohibit the delivery of many of the financial records maintained by a business located in China to third parties
absent Chinese government approval. Since discovery is an important part of proving a claim in litigation, and since most if not
all of the Company’s records are in China, Chinese secrecy laws could frustrate efforts to prove a claim against the Company
or its management. In order to commence litigation in the United States against an individual such as an officer or director, that
individual must be served. While directors and officers of a Delaware corporation are routinely served for purposes of a suit against
them in Delaware for breach of fiduciary duty and there are means of serving individuals who reside outside the United States in
other litigation, generally service requires the cooperation of the country in which a defendant resides. China has a history of
failing to cooperate in efforts to effect such service upon Chinese citizens in China. These and other similar PRC laws and regulations
could substantially impair our shareholders abilities to investigate and prosecute claims against our Company, our officers and
our directors.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
|
Item 8.
|
Indemnification of Directors and Officers
|
British Virgin Islands
law does limit the extent to which a company’s memorandum and articles of association may provide for indemnification of
officers and directors. China Ceramics’ memorandum and articles of association provides for indemnification of its officers
and directors for any liability incurred in their capacities as such, except through their own fraud or willful default to the
extent permitted under BVI law. Indemnification is only available to a person who acted in good faith and in what that person believed
to be in the best interests of China Ceramics.
Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling China Ceramics
pursuant to the foregoing provisions, China Ceramics has been informed that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act and is theretofore unenforceable.
* To be filed by amendment.
|
(1)
|
Incorporated by reference to exhibit of the same number filed with the Company’s Form 6-K filed with the SEC on December 20, 2019.
|
|
(2)
|
Incorporated by reference to exhibits of the same number filed with the Registrant’s Registration Statement on Form F-3 filed on April 16, 2018.
|
|
(3)
|
Incorporated by reference to exhibit of the same number filed
with the Company’s Form 6-K filed with the SEC on May 26, 2020.
|
|
(a)
|
The undersigned registrant hereby undertakes:
|
|
(1)
|
to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
|
|
(i)
|
To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
|
|
(ii)
|
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;
|
|
(iii)
|
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
|
Provided, however, that paragraphs
(a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information otherwise required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section
13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or
is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
|
(2)
|
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
|
(3)
|
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
|
|
(4)
|
To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering; provided, however, that a post-effective amendment need not be filed to include financial statements and information otherwise required by Section 10(a)(3) of the Act or §210.3-19 if such financial statements and information are contained in periodic reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this registration statement.
|
|
(5)
|
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
|
|
(i)
|
If the registrant is relying on Rule 430B:
|
|
(A)
|
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and
|
|
(B)
|
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or
|
|
(ii)
|
If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.
|
|
(6)
|
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:
|
The undersigned registrant undertakes that
in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of
the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell
such securities to such purchaser:
|
(i)
|
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and (iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
|
|
(b)
|
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
|
(c)
|
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
|
|
(d)
|
The undersigned registrant hereby further undertakes that:
|
|
(1)
|
For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4), or 497(h) under the Securities Act of 1933 shall be deemed to be part of this registration statement as of the time it was declared effective.
|
|
(2)
|
For the purpose of determining
any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
|
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form F-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunder
duly authorized, in the City of Jinjiang, Fujian Province, PRC on June 2, 2020.
|
China Ceramics Co., Ltd.
|
|
|
|
|
By:
|
/s/ Hen Man Edmund
|
|
|
Name:
|
Hen Man Edmund
|
|
|
Title:
|
Chief Financial Officer
|
Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities
and on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Huang Meishuang
|
|
Chief Executive Officer
|
|
June 2, 2020
|
|
|
(Principal Executive Officer and Director)
|
|
|
|
|
|
|
|
/s/ Hen Man Edmund
|
|
Chief Financial Officer
|
|
June 2, 2020
|
|
|
(Principal Financial Officer and
Principal Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Roy Tan Choon Kang
|
|
Director
|
|
June 2, 2020
|
|
|
|
|
|
/s/ Shen Cheng Liang
|
|
Director
|
|
June 2, 2020
|
|
|
|
|
|
/s/ Song Chungen
|
|
Director
|
|
June 2, 2020
|
|
|
|
|
|
/s/ Alex Ng Man Shek
|
|
Director
|
|
June 2, 2020
|
|
|
|
|
|
China Ceramics (NASDAQ:CCCL)
Historical Stock Chart
From Aug 2024 to Sep 2024
China Ceramics (NASDAQ:CCCL)
Historical Stock Chart
From Sep 2023 to Sep 2024